Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Frédéric Didelon has worked on the following 15 EPO patent applications which have been published in the last five years:

EP11764764

METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS

IPC classification:
A61K 39/395, C07K 16/24
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP11788502

NEW TREATMENTS OF HEPATITIS C VIRUS INFECTION

IPC classification:
A61K 31/7056, A61K 38/13, A61K 38/21, A61P 31/14
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP12736001

METHOD FOR TREATING METABOLIC DISORDERS

IPC classification:
A61K 39/395, C07K 16/28
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP12762605

ALISPORIVR FOR TREATMENT OF HEPATIS C VIRUS INFECTION

IPC classification:
A61K 31/14, A61K 38/13
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12727081

METHODS OF TREATING PSORIATIC ARTHRITIS (PSA) USING IL-17 ANTAGONISTS AND PSA RESPONSE OR NON- RESPONSE ALLELES

IPC classification:
A61K 39/395, C07K 16/24, C12Q 1/68, G01N 33/564
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13722740

PROCESS FOR THE MANUFACTURE OF CYCLIC UNDECAPEPTIDES

IPC classification:
C07K 7/64
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13814523

ACUTE KIDNEY INJURY

IPC classification:
G01N 33/68
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13717513

IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION

IPC classification:
C12Q 1/68, G01N 33/50, G01N 33/569
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13151551

Compositions and methods for use for antibodies against sclerostin

IPC classification:
A61K 31/663, A61K 39/00, A61K 39/395, A61K 45/06, C07K 16/18, C12N 15/13, C12N 15/63, G01N 33/68
Applicant:
Novartis AG
Agent:
Cameron John Marshall, Carpmaels & Ransford LLP
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
PATENT GRANTED
EP14756126

METHODS OF TREATING GENERALIZED PUSTULAR PSORIASIS (GPP) USING IL-17 ANTAGONISTS

IPC classification:
A61K 39/00, A61K 39/395, C07K 16/24
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP11716204

METHODS AND COMPOSITIONS FOR IMPROVING IMPLANT OSSEOINTEGRATION

IPC classification:
A61K 9/00, A61K 31/675, A61K 39/395, A61K 45/06, A61L 27/28, A61L 27/32, A61L 27/34, A61L 27/54, A61P 41/00
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP16163440

METHODS OF TREATING ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITIS USING ANTI-IL-17 ANTIBODIES

IPC classification:
A61K 31/519, A61K 39/395, A61P 37/06, C07K 16/24
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
Examination is in progress
EP15722260

METHODS OF IMPROVING OR ACCELERATING PHYSICAL RECOVERY AFTER SURGERY FOR HIP FRACTURE

IPC classification:
A61K 39/00, C07K 16/18, C07K 16/28
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15767597

USE OF IL-17 ANTAGONISTS TO INHIBIT THE PROGRESSION OF STRUCTURAL DAMAGE IN PSORIATIC ARTHRITIS PATIENTS

IPC classification:
A61K 39/00, C07K 16/24
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
Request for examination was made

Please Sign in to use this feature